Document:

Amended and Restated Investors' Rights Agreement

 EXHIBIT 4.6 
  

SALMEDIX, INC. 
  
 AMENDED AND RESTATED 
 INVESTORS’
RIGHTS AGREEMENT 
  
 March 30, 2004 

 TABLE OF CONTENTS 

									
	 	 	 	 	 	  	 	  	Page

	 	 	1.	 	Registration Rights	  	1
	 	 	 	 	1.1	  	 Definitions
	  	1
	 	 	 	 	1.2	  	 Request for Registration
	  	2
	 	 	 	 	1.3	  	 Company Registration
	  	3
	 	 	 	 	1.4	  	 Obligations of the Company
	  	4
	 	 	 	 	1.5	  	 Furnish Information.
	  	5
	 	 	 	 	1.6	  	 Expenses of Demand Registration.
	  	5
	 	 	 	 	1.7	  	 Expenses of Company Registration
	  	6
	 	 	 	 	1.8	  	 Underwriting Requirements
	  	6
	 	 	 	 	1.9	  	 Delay of Registration
	  	6
	 	 	 	 	1.10	  	 Indemnification
	  	7
	 	 	 	 	1.11	  	 Reports Under Securities Exchange Act of 1934
	  	8
	 	 	 	 	1.12	  	 Form S-3 Registration
	  	9
	 	 	 	 	1.13	  	 Assignment of Registration Rights
	  	10
	 	 	 	 	1.14	  	 Limitations on Subsequent Registration Rights
	  	10
	 	 	 	 	1.15	  	 “Market Stand-Off” Agreement.
	  	10
	 	 	 	 	1.16	  	 Termination of Registration Rights.
	  	11
				
	 	 	2.	 	Covenants of the Company.	  	11
	 	 	 	 	2.1	  	 Delivery of Financial Statements.
	  	11
	 	 	 	 	2.2	  	 Inspection
	  	12
	 	 	 	 	2.3	  	 Termination of Information and Inspection Covenants.
	  	12
	 	 	 	 	2.4	  	 Right of First Offer.
	  	12
	 	 	 	 	2.5	  	 Termination of Right of First Offer.
	  	14
	 	 	 	 	2.6	  	 Key-Person Insurance
	  	14
	 	 	 	 	2.7	  	 Stock Vesting
	  	14
	 	 	 	 	2.8	  	 Proprietary Information and Inventions Agreements.
	  	14
	 	 	 	 	2.9	  	 Indemnification Agreements.
	  	15
				
	 	 	3.	 	Miscellaneous.	  	15
	 	 	 	 	3.1	  	 Successors and Assigns.
	  	15
	 	 	 	 	3.2	  	 Governing Law
	  	15
	 	 	 	 	3.3	  	 Counterparts
	  	15
	 	 	 	 	3.4	  	 Titles and Subtitles
	  	15
	 	 	 	 	3.5	  	 Notices
	  	15
	 	 	 	 	3.6	  	 Expenses
	  	16
	 	 	 	 	3.7	  	 Amendments and Waivers
	  	16
	 	 	 	 	3.8	  	 Severability
	  	16
	 	 	 	 	3.9	  	 Aggregation of Stock
	  	16
	 	 	 	 	3.10	  	 Entire Agreement
	  	16
	 	 	 	 	3.11	  	 Delays or Omissions.
	  	16

  
 Schedule A    
Schedule of Investors 
  

 i 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
  
 THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the
30th day of March, 2004, by and among Salmedix, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”). This Agreement
amends and restated that certain Amended and Restated Investors’ Rights Agreement dated as of June 5, 2002, as amended through the date hereof (the “Prior Agreement”), by and among the Company and certain of the Investors. 

 
 RECITALS 
  
 WHEREAS, the Company and certain of the Investors are parties to the Series
C Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”); 
  
 WHEREAS, certain of the Investors are presently holders of the Company’s Series A Preferred Stock and Series B Preferred Stock and possess certain
rights to cause the Company to register shares of Common Stock issuable to such Investors and certain other matters pursuant to the Prior Agreement; 
  
 WHEREAS, the Company and two of the Investors are parties to those certain warrants dated January, 2002 and March 2004 for the purchase of shares of
Common Stock and Series C Preferred Stock of the Company, respectively (together, the “Warrants”); 
  
 WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company
pursuant to the Purchase Agreement, all of the Investors and the Company hereby desire to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement so that this Agreement shall govern the
rights of all of the Investors to cause the Company to register shares of Common Stock issuable to the Investors and certain other matters as set forth herein; 
  

NOW, THEREFORE, in consideration of the mutual promises set forth herein, and other good and valuable consideration the receipt and sufficiency of
which are hereby acknowledged, the parties hereto hereby agree that all of the provisions of the Prior Agreement shall be terminated and superseded and replaced in their entirety by this Agreement, in accordance with Section 3.7 of the Prior
Agreement, and the parties further agree as follows: 
  

	1.	Registration Rights. The Company covenants and agrees as follows: 

  
 1.1 Definitions. For purposes of this Section 1: 
  
 (a) The term “Act” means the Securities Act of 1933, as amended. 
  
 (b) The term “Form S-3” means such form under the Act as in effect on the date hereof or any registration form
under the Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
  
 (c) The term “Holder” means any person owning or having the right to acquire Registrable Securities or any
assignee thereof in accordance with Section 1.13 hereof. 
  

 1 

 (d) The term “1934 Act” shall mean the Securities Exchange Act of 1934, as amended. 

 
 (e) The terms “register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.

  
 (f) The term “Registrable Securities” means (i) the
Common Stock issuable or issued upon conversion of the Series A Preferred Stock, Series B Preferred Stock, or Series C Preferred Stock of the Company held by a Holder, (ii) the Common Stock issuable or issued upon exercise of the Warrants and (iii)
any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of the shares
referenced in (i) and (ii) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned. 
  
 (g) The number of shares of “Registrable Securities then outstanding” shall be determined by the number of shares
of Common Stock outstanding which are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities which are, Registrable Securities. 
  
 (h) The term “SEC” shall mean the Securities and Exchange Commission. 
  
 1.2 Request for Registration. 
  
 (a) If the Company shall receive at any time after the earlier of six months
following the Company’s initial public offering of securities or March 30, 2007, a written request from the Holders of a majority of the Registrable Securities then outstanding that the Company file a registration statement under the Act
covering the registration of the amount of securities having an anticipated aggregate offering price of at least $5,000,000, then the Company shall: 
  
 (i) within ten (10) days of the receipt thereof, give written notice of such request to all Holders; and 
  
 (ii) use its best efforts to effect as soon as practicable, and in any event
within ninety (90) days of the receipt of such request, the registration under the Act of all Registrable Securities which the Holders request to be registered, subject to the limitations of subsection 1.2(b), within twenty (20) days of the mailing
of such notice by the Company in accordance with Section 3.5. 
  
 (b) If the Holders initiating the registration request hereunder (“Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a
part of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and
shall be reasonably acceptable to the Company. In such event, the right of any Holder to include his Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of
such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities
through such underwriting shall (together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement 
  

 2 

 in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other
provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders,
in proportion (as nearly as practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be
reduced unless all other securities are first entirely excluded from the underwriting. 
  
 (c) Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.2, a certificate signed by the Chief Executive Officer of the Company stating
that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such
registration statement, the Company shall have the right to defer taking action with respect to such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided, however, that the
Company may not utilize this right more than once in any twelve-month period. 
  
 (d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.2: 
  
 (i) After the Company has effected two registrations pursuant to this Section 1.2 and such registrations have been declared
or ordered effective; 
  
 (ii) During the period starting with
the date ninety (90) days prior to the Company’s good faith estimate of the date of filing of a registration of the initial offering of the Company’s securities to the public, provided that the Company, within thirty (30) days of its
receipt of the Initiating Holders’ registration request, delivers written notice of such filing to all Holders; 
  
 (iii) During the period starting with the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a
registration of the initial offering of the Company’s securities to the public, provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; or 
  
 (iv) If the Initiating Holders propose to dispose of shares of Registrable
Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.12 below. 
  
 1.3 Company Registration. If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration
effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of
securities to participants in a Company stock plan, a registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities
or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section 1.8, cause to be registered under
the Act all of the Registrable Securities that each such Holder has requested to be registered. 
  

 3 

 1.4 Obligations of the Company. Whenever required under this Section 1 to effect the registration
of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the
Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or until the distribution contemplated in the Registration Statement has been
completed; provided, however, that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common
Stock (or other securities) of the Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such 120-day period shall be extended, if necessary, to
keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules
under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (I) includes any prospectus required by Section 10(a)(3) of the Act or (II) reflects facts or events representing a
material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (I) and (II) above to be contained in periodic reports filed pursuant to Section 13
or 15(d) of the 1934 Act in the registration statement. 
  
 (b)
Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the
disposition of all securities covered by such registration statement. 
  
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the
disposition of Registrable Securities owned by them. 
  
 (d) Use
its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 
  
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
  
 (f) Notify each Holder of Registrable Securities covered by such registration
statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
  

 4 

 (g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities
exchange on which similar securities issued by the Company are then listed. 
  
 (h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such
registration. 
  
 (i) Use its reasonable efforts to furnish, on
the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (A) an opinion of counsel representing the Company for the purposes of such registration, dated as of such
date and in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (B) a letter, dated as of such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by the independent certified public accounts to underwriters in an underwritten public offering addressed to the underwriters. 
  
 1.5 Furnish Information. 
  
 (a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable
Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect the
registration of such Holder’s Registrable Securities. 
  
 (b)
The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.12 if, due to the operation of subsection 1.5(a), the number of shares or the anticipated aggregate offering price of the
Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as
specified in subsection 1.2(a) or subsection 1.12(b)(2), whichever is applicable. 
  
 1.6 Expenses of Demand Registration. All expenses (other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Section 1.2 related to the
Registrable Securities), including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel
for the selling Holders (such counsel’s fees and disbursements not to exceed $25,000) shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun
pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of Holders holding at least a majority of the Registrable Securities to be registered, unless such withdrawal is based upon material adverse information
relating to the Company that is different from information not previously known or available to the selling Holders. In the event that the Company shall not be required to pay for the aforementioned expenses of registration, the selling Holders
shall bear any and all such expenses, unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2. 
  
 1.7 Expenses of Company Registration. The Company shall bear and pay all expenses incurred in connection with any
registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder (which right may be assigned as provided in Section 1.13), including (without limitation) all registration,
filing and qualification fees, printers’ and accounting fees relating or apportionable thereto and the fees and disbursements of one counsel (such counsel’s fees and disbursements not to exceed $25,000) for the selling Holders selected by
them, but excluding underwriting discounts and commissions relating to Registrable Securities. 
  

 5 

 1.8 Underwriting Requirements. In connection with any offering involving an underwriting of shares
of the Company’s capital stock, the Company shall not be required under Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the
underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not, jeopardize the success of the offering by the Company. If the
total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is
compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole discretion will not
jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such
other proportions as shall mutually be agreed to by such selling stockholders) but in no event shall (i) the amount of securities of the selling Holders included in the offering be reduced below twenty-five percent (25%) of the total amount of
securities included in such offering, unless such offering is the initial public offering of the Company’s securities in which case the selling stockholders may be excluded if the underwriters make the determination described above and no other
stockholder’s securities are included; (ii) notwithstanding (i) above, any shares being sold by a stockholder exercising a demand registration right similar to that granted in Section 1.2 be excluded from such offering; or (iii) the securities
of the selling Holders be excluded from the underwriting before any other party’s securities are first excluded from such registration. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a
holder of Registrable Securities and which is a partnership, corporation or limited liability company, the partners, former partners, stockholders, members or former members of such holder, or the estates and family members of any such partners,
former partners, members or former members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder,” and any pro-rata reduction with respect to such “selling stockholder”
shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “selling stockholder,” as defined in this sentence. 
  
 1.9 Delay of Registration. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 
  
 1.10 Indemnification. In the event any Registrable Securities are
included in a registration statement under this Section 1: 
  
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the
Act or the 1934 Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or
actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such
registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state 
  

 6 

 securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the
Company will pay to each such Holder, underwriter or controlling person any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided,
however, that the indemnity agreement contained in this subsection 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and
in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person. 
  

(b) To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who
has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such
underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims,
damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in
connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided, that, in no event shall any indemnity under this subsection 1.10(b) exceed the net
proceeds from the offering received by such Holder. 
  
 (c)
Promptly after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any
other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented
without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party (subject to the limitations contained herein), if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice
to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.10,
but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.10. 
  
 (d) If the indemnification provided for in this Section 1.10 is held by a
court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder,
shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the 
  

 7 

 relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the
statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. In no event shall any contribution by a Holder hereunder exceed the net proceeds from the offering received by such Holder.

  
 (e) The obligations of the Company and Holders under this
Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and the termination of other provisions of this Agreement. No indemnifying party, in the defense of any such claim
or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party a release from all liability in respect to such claim or litigation. 
  
 1.11 Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any
time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to: 
  
 (a) make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after ninety (90) days after the
effective date of the first registration statement filed by the Company for the offering of its securities to the general public; 
  
 (b) take such action, including the voluntary registration of its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the Holders to
utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for the offering of its securities to the
general public is declared effective; 
  
 (c) file with the SEC in
a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and 
  
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it
has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to
such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other
reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or
pursuant to such form. 
  
 1.12 Form S-3 Registration. In
case the Company shall receive from any Holder or Holders a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned
by such Holder or Holders, the Company will: 
  

 8 

 (a) promptly give written notice of the proposed registration, and any related qualification or
compliance, to all other Holders; and 
  
 (b) as soon as
practicable, effect such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities
as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice
from the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.12: (1) if Form S-3 is not available for such offering by the Holders; (2)
if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any
underwriters’ discounts or commissions) of less than $1,000,000; (3) if the Company shall furnish to the Holders a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board of
Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such Form S-3 Registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than 120 days after receipt of the request of the Holder or Holders under this Section 1.12; provided, however, that the Company shall not utilize this right more than once in any twelve month
period; (4) if the Company has already effected a registration on Form S-3 for the Holders pursuant to this Section 1.12 during the preceding six months; or (5) in any particular jurisdiction in which the Company would be required to qualify to do
business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 
  
 (c) Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be
registered as soon as practicable after receipt of the request or requests of the Holders. All expenses incurred in connection with a registration requested pursuant to Section 1.12, including (without limitation) all registration, filing,
qualification, printer’s and accounting fees and the reasonable fees and disbursements of one counsel for the selling Holder or Holders (not to exceed $25,000) and counsel for the Company, shall be borne by the Company. Registrations effected
pursuant to this Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively. 
  
 1.13 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be
assigned (but only with all related obligations) by a Holder to (i) any limited partner, general partner, or former partner of a Holder which is a partnership, (ii) any spouse, ancestor, lineal descendant or sibling of a Holder who is an individual,
(iii) any trust for the benefit of a transferee or assignee of such securities, (iv) any transferee who acquires at least Fifty Thousand (50,000) shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends,
combinations and other recapitalizations), (v) any member or former member of a Holder which is a limited liability company, provided: (i) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and
address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (ii) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement,
including without limitation the provisions of Section 1.15 below; and (iii) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under
the Act. For the purposes of determining the number of shares of Registrable Securities held by a transferee or assignee, the holdings of transferees and assignees of a partnership who are partners or former partners of such partnership and members
or former members of a Holder which is a limited liability company (including spouses, ancestors, lineal descendants and siblings of such partners or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be
aggregated 
  

 9 

 together and with the partnership or limited liability company, as applicable; provided that all assignees and
transferees who would not qualify individually for assignment of registration rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices or taking any action under this Section 1. 
  
 1.14 Limitations on Subsequent Registration Rights. From and after the
date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company
which would allow such holder or prospective holder to include such securities in any registration filed under Sections 1.2, 1.3 or 1.12 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities
in any such registration only to the extent that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included. 
  
 1.15 “Market Stand-Off” Agreement. Each Investor hereby agrees that, during the period of duration
specified by the Company and an underwriter of common stock or other securities of the Company, following the effective date of the registration statements of the Company described in clause (b) below filed under the Act, it shall not, to the extent
requested by the Company and such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other than to donees who
agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration; provided, however, that: 
  
 (a) all officers and directors of the Company, all holders of at least 1% of the Company’s outstanding capital stock
and all other persons with registration rights (whether or not pursuant to this Agreement) enter into similar agreements; 
  
 (b) such market stand-off time period shall not exceed one hundred eighty (180) days in the case of the initial offering of the Company’s securities
to the public, or ninety (90) days in the case of the next subsequent offering of the Company’s securities to the public; and 
  
 (c) except in the case of the initial offering of the Company’s securities to the public, such market stand-off shall not apply to securities
excluded from such registration by operation of the underwriter’s discretion to exclude securities pursuant to Section 1.8 of this Agreement. 
  
 In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Investor
(and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 
  
 Notwithstanding the foregoing, the obligations described in this Section 1.15 shall not apply to a registration relating solely to employee benefit plans
on Form S-l or Form S-8 or similar forms which may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms which may be promulgated in the future. 
  
 1.16 Termination of Registration Rights. 
  
 (a) No Holder shall be entitled to exercise any right provided for in this
Section 1 after five (5) years following the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the initial firm commitment underwritten offering of its securities to the
general public. 
  

 10 

 (b) In addition, the right of any Holder to request registration or inclusion in any registration
pursuant to Section 1.3 shall terminate on or after the closing of the first Company-initiated registered public offering of Common Stock of the Company, provided that (i) the Company is subject to the provisions of the 1934 Act, (ii) such Holder
holds less than one percent (1%) of the Company’s outstanding stock and (iii) all shares of Registrable Securities held by and issuable to such Holder may immediately be sold under Rule 144 during any ninety (90) day period. 
  
 2. Covenants of the Company. 
  
 2.1 Delivery of Financial Statements. The Company shall deliver to
each Investor: 
  
 (a) provided such Investor holds shares of
Registrable Securities, as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s
equity as of the end of such year, and a schedule as to the sources and applications of funds for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles
(“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company; 
  
 (b) provided such Investor holds shares of Registrable Securities, as soon as practicable, but in any event within forty-five (45) days after the end of
each of the first three (3) quarters of each fiscal year of the Company, an unaudited profit or loss statement, schedule as to the sources and application of funds for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal
quarter; 
  
 (c) provided such Investor holds at least 250,000
shares of Registrable Securities (each, a “Major Investor”), within thirty (30) days of the end of each month, an unaudited income statement and schedule as to the sources and application of funds and balance sheet for and as of the end of
such month, in reasonable detail and for the current fiscal year to date, a comparison to plan figures for such period, prepared in accordance with generally accepted accounting principles consistently applied, with the exception that no notes need
be attached to such statements and year end audit adjustments may not have been made; 
  
 (d) provided such Investor is a Major Investor, as soon as practicable, but in any event thirty (30) days following its approval by the Company’s Board of Directors, a budget and business plan for the next fiscal
year, prepared on a monthly basis, including balance sheets and sources and applications of funds statements for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; 
  
 (e) with respect to the financial statements called for in subsections (b)
and (c) of this Section 2.1, an instrument executed by the Chief Financial Officer or President of the Company and certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods
(with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment; and 
  
 (f) such other information relating to the financial condition, business,
prospects or corporate affairs of the Company as the Investor or any assignee of the Investor may from time to time request, provided, however, that the Company shall not be obligated under this subsection (f) or any other subsection of
Section 2.1 to provide information which it deems in good faith to be a trade secret or similar confidential information. 
  

 11 

 2.2 Inspection. The Company shall permit each Investor, at such Investor’s expense, to visit
and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information which it reasonably considers to be a trade secret or similar confidential information. 
  
 2.3 Termination of Information and Inspection Covenants. The covenants
set forth in subsections 2.1(a), (b), (c), (d) and (f) and Section 2.2 shall terminate as to Investors and be of no further force or effect when the sale of securities pursuant to a registration statement filed by the Company under the Act in
connection with the firm commitment underwritten offering of its securities to the general public is consummated or when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever
event shall first occur. 
  
 2.4 Right of First Offer.
Subject to the terms and conditions specified in this paragraph 2.4, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). For the purposes of
determining a Major Investor under this Section 2.4, the Company shall aggregate all Registrable Securities held by an Investor, its partners or members, and any of its affiliates. A Major Investor shall be entitled to apportion the right of first
offer hereby granted it among itself and its partners, members and affiliates in such proportions as it deems appropriate. 
  
 Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock
(“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions: 
  
 (a) The Company shall deliver a notice by certified mail (“Notice”) to the Major Investors stating (i) its bona fide intention to offer such
Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 
  
 (b) Within 20 calendar days after giving of the Notice, the Major Investor may elect to purchase or obtain, at the price and on the terms specified in the
Notice, up to that portion of such Shares which equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by such Major Investor bears to the total number of shares
of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible or exercisable securities). The Company shall promptly, in writing, inform each Major Investor which purchases all the shares available to it
(a “Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten-day period commencing after such information is given, each Fully-Exercising Investor shall be entitled to obtain that portion of the
Shares for which other Major Investors were entitled to subscribe but which were not subscribed for by the Major Investors which is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of
Preferred Stock then held, by such Fully-Exercising Investor bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase
some of the unsubscribed shares. 
  
 (c) If all Shares referred to
in the Notice are not elected to be obtained as provided in subsection 2.4(b) hereof, the Company may, during the 30-day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the remaining unsubscribed portion of
such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of 
  

 12 

 the Shares within such period, or if such agreement is not consummated within 30 days of the execution thereof, the right
provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
  
 (d) The right of first offer in this paragraph 2.4 shall not be applicable to (i) the issuance or sale of Common Stock issued pursuant to a stock dividend
or a split, subdivision, or recapitalization of the outstanding shares of Common Stock of the Company, (ii) shares of Common Stock issuable or issued to employees, consultants, directors or officers of the Company pursuant to a stock option plan or
restricted stock plan approved by the Board of Directors, (iii) shares of Common Stock issued in connection with a bona fide acquisition of another business entity or business segment of another business entity by the Company, whether by merger,
consolidation, sale of assets or sale or exchange of stock, whereby the Company will own more than 50% of the voting stock of such business entity or business segment, provided that such transaction is approved by the Board of Directors of the
Company including the directors elected by the holders of Series A Preferred Stock then serving as directors of the Company, the directors elected by the holders of Series B Preferred Stock then serving as directors of the Company and the directors
elected by the holders of Series C Preferred Stock then serving as directors of the Company, (iv) shares of Common Stock issued to financial institutions or lessors in connection with commercial credit arrangements, equipment financings, or similar
transactions which are approved by the Board of Directors, (v) shares of Common Stock issued upon conversion of the Preferred Stock, (vi) shares of Common Stock issued or issuable in connection with corporate partnering, licensing or other strategic
transactions on terms approved by the Board of Directors, including the directors elected by the holders of Series A Preferred Stock then serving as directors of the Company, the directors elected by the holders of Series B Preferred Stock then
serving as directors of the Company and the directors elected by the holders of Series C Preferred Stock then serving as directors of the Company, and provided that such issuances are for other than primarily equity financing purposes, (vii) shares
of Common Stock issued or issuable (1) in a public offering before or in connection with which all outstanding shares of Preferred Stock will be converted to Common Stock or (2) upon exercise of warrants or rights granted to underwriters in
connection with such a public offering; and (viii) any right, option, or warrant to acquire any security convertible into any security excluded from the operation of this right of first offer pursuant to subsections (ii) through (vii) above.

  
 (e) Except as provided for herein, the right of first offer
set forth in this Section 2.4 may not be assigned or transferred. 
  
 2.5 Termination of Right of First Offer. The rights set forth in Section 2.4 and hereof shall terminate and be of no further force or effect upon, and shall not apply to, the sale of securities pursuant to a registration statement
filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public. 
  
 2.6 Key-Person Insurance. The Company shall obtain and maintain in full force and effect until such time as the Board of Directors determines that
such insurance should be discontinued, term life insurance in the amount of $1,000,000 on the life of each of two key executives of the Company, one from each of the following two categories: (i) its Chief Executive Officer or President, and (ii)
its Chief Operating Officer, with proceeds payable to the Company, such insurance to be obtained at such time as each such position is filled. 
  
 2.7 Stock Vesting. Unless otherwise approved by the Board of Directors, all stock options and other stock equivalents issued after the date of this
Agreement to employees, directors and consultants shall be subject to a right of first refusal in favor of the Company and vesting as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of the first year of such service, and
(b) seventy-five (75%) of such stock shall vest thereafter in monthly increments over the remaining three (3) 
  

 13 

 years. With respect to any shares of Common Stock purchased by such person, the Company’s repurchase option shall
provide that upon such person’s termination of employment or service to the Company, with or without cause, the Company or its assignee shall have the option to purchase at cost any unvested shares of stock held by such person. Unless
previously terminated by the Board of Directors, the foregoing obligations shall terminate and be of no further force or effect upon the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with
the firm commitment underwritten offering of its securities to the general public. 
  
 2.8 Proprietary Information and Inventions Agreements. The Company shall require all officers and employees to execute a Proprietary Information and Inventions Agreement and shall require all consultants to
execute a Consulting Agreement, each agreement in a form approved by the Board of Directors. The foregoing obligations shall terminate and be of no further force or effect upon the sale of securities pursuant to a registration statement filed by the
Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public. 
  
 2.9 Indemnification Agreements. The Company shall use best efforts to provide and execute indemnification agreements with each Company director and
executive officer within thirty (30) days of the date of this Agreement. 
  
 3.
Miscellaneous. 
  
 3.1 Successors and Assigns. Except
as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing
in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. 
  
 3.2 Governing
Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 
  
 3.3 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Purchasers of Series C Preferred Stock in a subsequent sale pursuant to Section 1.3 of the Purchase Agreement shall
execute counterpart signature pages to this Agreement and shall become parties hereto without the need of further action, signature or approval by the other Investors, under Section 3.7 of this Agreement or otherwise. 
  
 3.4 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 3.5 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal delivery to the party to be notified or upon deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the address indicated for such
party on the signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties. 
  

 14 

 3.6 Expenses. If any action at law or in equity is necessary to enforce or interpret the terms of
this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
  
 3.7 Amendments and Waivers. Any term of this Agreement may be amended
and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Registrable
Securities then outstanding. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities, and the Company.

  
 3.8 Severability. If one or more provisions of this
Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with
its terms. 
  
 3.9 Aggregation of Stock. All shares of
Registrable Securities held or acquired by affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 3.10 Entire Agreement. This Agreement (including the Exhibits hereto, if any) constitutes the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. 
  
 3.11 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power, or remedy accruing to any Holder, upon any breach,
default or noncompliance of the Company under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of any similar breach,
default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any Holder’s part of any breach, default or noncompliance under the Agreement or any waiver on such
Holder’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement, by law, or otherwise afforded to
Holders, shall be cumulative and not alternative. 
  
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK] 
  

 15 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

					
	 	 	 SALMEDIX, INC.,
 a Delaware corporation

			
	 	 	 By:
	 	 /s/    DAVID S. KABAKOFF

	 	 	 	 	 David S. Kabakoff

	 	 	 Its:
	 	 Chief Executive Officer

		
	 Address:
	 	9380 Judicial Drive
	 	 	 San Diego, California 92121

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 INTERWEST PARTNERS VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	2710 Sand Hill Road
	 	 	Menlo Park, CA 94025
		
	 	 	 INTERWEST INVESTORS VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	2710 Sand Hill Road
	 	 	Menlo Park, CA 94025
		
	 	 	 INTERWEST INVESTORS Q VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 2710 Sand Hill Road

	 	 	 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 VERSANT VENTURE CAPITAL I, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260

	 	 	 Menlo Park, CA 94025

		
	 	 	 VERSANT SIDE FUND I, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260

	 	 	 Menlo Park, CA 94025

		
	 	 	 VERSANT AFFILIATES FUND I-A, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260

	 	 	 Menlo Park, CA 94025

		
	 	 	 VERSANT AFFILIATES FUND I-B, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260

	 	 	 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 ALEXANDRIA EQUITIES, LLC,
 a Delaware limited liability company

			
	 	 	 By:
	 	 ARE-QRS CORP., a Maryland corporation

			
	 	 	 By:
	 	 /s/    JOEL S. MARCUS

	 	 	 	 	 Joel S. Marcus

	 	 	 Its:
	 	 Chief Executive Officer

		
	 Address:
	 	 135 North Los Robles Avenue

	 	 	 Suite 250

	 	 	 Pasadena, California 91101

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 CMEA VENTURES LIFE SCIENCES 2000, L.P.

			
	 	 	 By:
	 	 /s/    M. SCHREIBSTEIN

			
	 	 	 Its:
	 	 General Partner

		
	 Address:
	 	 One Embarcadero Center, Suite 3250

	 	 	 San Francisco, CA 94111

	 	 	 ATTN: Meryl L. Schreibstein

		
	 	 	 CMEA VENTURES LIFE SCIENCES 2000,
 Civil Law Partnership

			
	 	 	 By:
	 	 /s/    M. SCHREIBSTEIN

			
	 	 	 Its:
	 	 General Partner

		
	 Address:
	 	 One Embarcadero Center, Suite 3250

	 	 	 San Francisco, CA 94111

	 	 	 ATTN: Meryl L. Schreibstein

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 DELPHI VENTURES V, L.P.

			
	 	 	 By:
	 	 Delphi Management Partners V, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    DEEPA PAKIANATHAN

	 	 	 Its:
	 	 Managing Member

		
	 Address:
	 	 3000 Sand Hill Road

	 	 	 Suite 135, Building 1

	 	 	 Menlo Park, CA 94025

		
	 	 	 DELPHI BIOINVESTMENTS V, L.P.

			
	 	 	 By:
	 	 Delphi Management Partners V, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    DEEPA PAKIANATHAN

	 	 	 Its:
	 	 Managing Member

		
	 Address:
	 	 3000 Sand Hill Road

	 	 	 Suite 135, Building 1

	 	 	 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 ABERDARE VENTURES II, L.P.

			
	 	 	 By:
	 	 Aberdare GP II, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 Paul H. Klingenstein

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 One Embarcadero Center, Suite 4000

	 	 	 San Francisco, CA 94111

		
	 	 	 ABERDARE VENTURES II (Bermuda), L.P.

			
	 	 	 By:
	 	 Aberdare GP II, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 Paul H. Klingenstein

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 One Embarcadero Center, Suite 4000

	 	 	 San Francisco, CA 94111

		
	 	 	 PAUL H. KLINGENSTEIN

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 An individual investor

		
	 Address:
	 	 One Embarcadero Center, Suite 4000

	 	 	 San Francisco, CA 94111

		
	 	 	 JOHN H. ODDEN

			
	 	 	 By:
	 	 /s/    JOHN H. ODDEN

	 	 	 	 	 An individual investor

		
	 Address:
	 	 One Embarcadero Center, Suite 4000

	 	 	 San Francisco, CA 94111

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

			
	 VENTURES WEST 7 LIMITED PARTNERSHIP

		
	 By:
	 	 Ventures West 7 Management Ltd.

	 Its:
	 	 General Partner

		
	 By:
	 	 /s/ SAM [illegible]

	 Its:
	 	 Senior Vice President

		
	 By:
	 	 /s/    HOWARD RIBACK

	 	 	 Howard Riback

	 Its:
	 	 Vice President, Finance and Administration

		
	 	 	 Address: 1285 West Pender Street

	 	 	                  Vancouver, B. C. V6E
4B1

	
	 VENTURES WEST 7 U.S. LIMITED PARTNERSHIP

		
	 By:
	 	 Ventures West 7 Management (International) Inc.

	 Its:
	 	 Manager

		
	 By:
	 	 /s/ SAM [illegible]

	 Its:
	 	 Senior Vice President

		
	 By:
	 	 /s/    HOWARD RIBACK

	 	 	Howard Riback
	 Its:
	 	 Vice President, Finance and Administration

		
	 	 	 Address: 1285 West Pender Street

	 	 	                  Vancouver, B. C. V6E
4B1

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 BIOFRONTIER GLOBAL INVESTMENT PARTNERSHIP
 a Japanese civil law partnership

			
	 	 	 By:
	 	 Biofrontier Partners Co., Ltd.

	 	 	 Its:
	 	     General Partner

			
	 	 	 By:
	 	 /s/    YOSHIHIRO OHTAKI

	 	 	 	 	 Yoshihiro Ohtaki

	 	 	 Its:
	 	     President

		
	 Address:
	 	 K.I. Kousan Tokyo Building, 3rd Floor

	 	 	 2-3-14 Yaesu, Chuo-ku

	 	 	 Tokyo, Japan 104-0028

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

							
	 	 	 GENECHEM THERAPEUTICS VENTURE FUND L.P.

			
	 	 	 By:
	 	GeneChem Therapeutics, Inc.
	 	 	 Its:
	 	General Partner
				
	 	 	 	 	By:	 	 GeneChem Management, Inc.

				
	 	 	 	 	By:	 	 /s/    LOUIS LACASSE

	 	 	 	 	 	 	 Louis Lacasse

	 	 	 	 	Its:	 	 President

		
	 Address:
	 	 1001, de Maisonneuve O., Suite 920

	 	 	 Montreal, Quebec

	 	 	 Canada H3A 3C8

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 PROQUEST INVESTMENTS II, L.P.

			
	 	 	 By:
  
	 	 /s/    PASQUALE DEANGELIS

	 	 	 	 	 Pasquale DeAngelis

	 	 	 Its:
	 	 Chief Financial Officer

		
	 	 	 PROQUEST INVESTMENTS II ADVISORS FUND, L.P.

			
	 	 	 By:
  
	 	 /s/    PASQUALE DEANGELIS

	 	 	 	 	 Pasquale DeAngelis

	 	 	 Its:
	 	 Chief Financial Officer

		
	 	 	 QS MEDIX INC.

			
	 	 	 By:
  
	 	 /s/    CRAIGMUIR CHAMBERS

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 Craigmuir Chambers

	 	 	 P. O. Box 71

	 	 	 Road Town Tortola

	 	 	 British Virgin Islands

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 H.I.G. SALMEDIX, INC.

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/    [illegible]

			
	 	 	 Its:
	 	 
		
	 Address:
	 	 H.I.G. Salmedix, Inc.

	 	 	 c/o Maples & Calder

	 	 	 P.O. Box 309, Ugland House

	 	 	 South Church Street, George Town

	 	 	 Grand Cayman, Cayman Islands

		
	 	 	 With copies to:

		
	 	 	 Aaron Davidson

	 	 	 Managing Director

	 	 	 H.I.G. Ventures

	 	 	 1001 Brickell Bay Drive

	 	 	 27th Floor

	 	 	 Miami, FL 33131

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 EASTON HUNT CAPITAL PARTNERS, L.P.

			
	 	 	 By:
	 	 EHC GP, L.P.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 EHC, INC.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
  
	 	 /s/    RICHARD P. SCHNEIDER

	 	 	 	 	 Richard P. Schneider

			
	 	 	 Its:
	 	 Vice President & Secretary

			
	 Address:
	 	 	 	 641 Lexington Avenue – 21st floor
 New York, NY
10022

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 HUNT VENTURES, L.P.

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/    FULTON MURRAY III

			
	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 1445 Ross Avenue
 Suite 1500

	 	 	 Dallas, TX 75202

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 NOVO A/S

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
	 	 /s/    [illegible]

	 	 	 Its:
	 	 
			
	 Address:
	 	 	 	 Novo A/S
 Krogshojvej 41
 DK – 2880 Bogsvaerd

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 CLARIDEN BANK, as custodian for the Clariden
 Biotech Equity Fund

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
	 	 /s/    E. [illegible]

			
	 	 	 Its:
	 	 Executive Vice President

			
	 Address:
	 	 	 	 

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 CADUCEUS PRIVATE INVESTMENTS II, LP

			
	 	 	 By:
	 	 OrbiMed Capital II LLC

			
	 	 	 	 	  
 /s/    [illegible]

	 	 	 	 	 General Partner

	 	 	 	 	 OrbiMed Capital LLC

	 	 	 	 	 767 3rd Avenue, 30th Floor

	 	 	 	 	 New York, NY 10017

	 	 	 	 	 Attn: Eric Bittelman, CFO

		
	 	 	 CADUCEUS PRIVATE INVESTMENTS II (QP), LP

			
	 	 	 By:
	 	 OrbiMed Capital II LLC

			
	 	 	 	 	  
 /s/    [illegible]

	 	 	 	 	 General Partner

	 	 	 	 	 OrbiMed Capital LLC

	 	 	 	 	 767 3rd Avenue, 30th Floor

	 	 	 	 	 New York, NY 10017

	 	 	 	 	 Attn: Eric Bittelman, CFO

		
	 	 	 UBS JUNIPER CROSSOVER FUND, L.L.C.

			
	 	 	 By:
	 	 OrbiMed Advisors LLC

			
	 	 	 	 	  
 /s/    [illegible]

	 	 	 	 	 Member of UBS Juniper Crossover

	 	 	 	 	 Management, L.L.C.

	 	 	 	 	 Managing Member

		
	 Address:
	 	 PFPC Trust
 8800 Tinicum Blvd., 3rd Floor
 Philadelphia, PA 19153
 Attn: Eric Kessler

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

					
	 	 	 SG COWEN SECURITIES CORPORATION

			
	 	 	 By:
	 	 /s/    CHARLES E. MATHER

			
	 	 	 Its:
	 	 Charles E. Mather, Managing Director

		
	 Address:
	 	 1221 Avenue of the Americas
 New York, NY 10020

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED 
 INVESTORS’ RIGHTS AGREEMENT] 

 SCHEDULE A 
  

SCHEDULE OF INVESTORS 
  
 InterWest Partners VIII, L.P. 
 InterWest Investors VIII, L.P. 
 InterWest Investors Q VIII, L.P. 
 Versant Venture Capital I, L.P. 

Versant Side Fund I, L.P. 
 Versant Affiliates Fund I-A, L.P. 

Versant Affiliates Fund I-B, L.P. 
 Alexandria Equities, LLC 
 CMEA Ventures Life Sciences 2000, L.P. 
 CMEA Ventures Life Sciences 2000, a
Civil Law Partnership 
 Delphi Ventures V, L.P. 
 Delphi
BioInvestments V, L.P. 
 ProQuest Investments II, L.P. 
 ProQuest
Investments II Advisors Fund, L.P. 
 Ventures West 7 Limited Partnership 
 Ventures West 7 U.S. Limited Partnership 
 Biofrontier Global Investment Partnership 
 GeneChem Therapeutics Venture Fund L.P. 
 Aberdare Ventures II, L.P. 
 Aberdare Ventures II (Bermuda), L.P. 
 Paul H. Klingenstein 
 John H. Odden 
 H.I.G. Salmedix, Inc. 
 Caduceus Private Investments II, LP 
 Caduceus Private Investments II (QP), LP

 UBS Juniper Crossover Fund, LLC 
 Easton Hunt Capital Partners,
L.P. 
 Hunt Ventures, L.P. 
 Novo A/S 
 Clariden Bank 
 QS Medix Inc. 
 SG Cowen Securities CorporationAmended and Restated Stockholders' Agreement

 EXHIBIT 4.7 
  
 SALMEDIX, INC. 
  
 AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 
  
 March 30, 2004 

 AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 
  
 This Amended and Restated Stockholders’ Agreement (this
“Agreement”) is made as of the 30th day of March, 2004 by and among Salmedix, Inc., a Delaware corporation (the “Company”), the initial stockholders of the Company listed on Schedule A attached hereto (collectively, the
“Founders” and individually, a “Founder”), certain holders of Series A Preferred Stock listed on Schedule A attached hereto (the “Series A Holders”), certain holders of Series B Preferred Stock listed on
Schedule A attached hereto (the “Series B Holders”) and certain holders of Series C Preferred Stock as well as the holder (the “Holder”) of a warrant to purchase shares of Series C Preferred Stock (the “Warrant”)
listed on Schedule A attached hereto (collectively, and including the Holder to the extent such Warrant has been exercised, the “Series C Holders”). The Series A Holders, the Series B Holders and the Series C Holders are
collectively referred to herein as the “Stockholders” and individually as a “Stockholder.” This Agreement terminates and replaces in full that certain Stockholders’ Agreement dated as of June 5, 2002, as amended through the
date hereof (the “Prior Agreement”), by and among the Company, the Founders, the Series A Holders and the Series B Holders. 
  
 WHEREAS, pursuant to that certain Series C Preferred Stock Purchase Agreement (the “Purchase Agreement”) dated as of the date hereof among the
Company and the Series C Holders, certain of the Series C Holders are purchasing shares of the Company’s Series C Preferred Stock (the “Series C Preferred Stock”); 
  
 WHEREAS, the Series A Holders and the Series B Holders are presently holders of the Company’s Series A Preferred Stock
(the “Series A Preferred Stock”) and Series B Preferred Stock (together with the Series C Preferred Stock, the “Preferred Stock”) and possess certain rights and are subject to certain obligations pursuant to the Prior Agreement;

  
 WHEREAS, the Founders are the beneficial owners of shares of
the Company’s common stock (the “Stock,” which term for purposes of this Agreement also includes any additional shares of the Company’s capital stock now owned or hereafter acquired by the Founders, including without limitation,
shares of the Company’s common stock and Preferred Stock); 
  
 WHEREAS, in order to induce the Series C Holders to purchase the Series C Preferred Stock, the Company, the Stockholders and the Founders hereby desire to accept the rights and obligations pursuant to this Agreement in lieu of the rights
and obligations pursuant to the Prior Agreement so that this Agreement shall govern the rights and obligations of the Stockholders, the Founders and the Company and certain other matters as set forth herein; and 
  
 NOW, THEREFORE, in consideration of the mutual promises set forth herein, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree that the Prior Agreement and all of the provisions thereof are hereby terminated and superseded and replaced in
their entirety by this Agreement, in accordance with Section 6.3 of the Prior Agreement, and the parties further agree as follows: 
  
 1. Co-Sale Right. 
  
 (a) If any Founder proposes to sell or transfer any shares of Stock (other than exempt transfers as set forth in Section 2) then such Founder shall
promptly give written notice (the “Notice”) to the Company and the Stockholders at least twenty (20) days prior to the closing of such sale or transfer. The Notice shall describe in reasonable detail the proposed sale or transfer
including, without limitation, the number of shares of Stock to be sold or transferred, the nature of such sale or transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. In the 

 event that the sale or transfer is being made pursuant to the provisions or paragraph 2(a) or 2(b) hereof, then such
Founder shall promptly give written notice to the Company at least twenty (20) days prior to the closing of such sale or transfer and shall state under which paragraph the sale or transfer is being made. 
  
 (b) Each Stockholder shall have the right, exercisable upon written notice
to such Founder within fifteen (15) days after receipt of the Notice, to participate in such sale of Stock on the same terms and conditions. To the extent one or more of the Stockholders exercises such right of participation in accordance with the
terms and conditions set forth below, the number of shares of Stock that the Founder may sell in the transaction shall be correspondingly reduced. 
  
 (c) Each Stockholder may sell all or any part of that number of shares of Stock equal to the product obtained by multiplying (i) the aggregate number of
shares of Stock covered by the Notice by (ii) a fraction the numerator of which is the number of shares of Common Stock owned by the Stockholder at the time of the sale or transfer and the denominator of which is the total number of shares of Common
Stock owned by the Founder and the Stockholders at the time of the sale or transfer. For purposes of this Agreement, “Common Stock” shall mean shares of the Company’s common stock and shares of the Company’s common stock issued
or issuable upon conversion of shares of Preferred Stock. 
  
 (d)
If any Stockholder fails to elect to fully participate in such Founder’s sale pursuant to this Section 1, the Founder shall give notice of such failure to the Stockholders who did so elect (the “Participants”). Such notice may be made
by telephone if confirmed in writing within two (2) days. The Participants shall have five (5) days from the date such notice was given to agree to sell their pro rata share of the unsold portion. For purposes of this paragraph, a Participant’s
pro rata share shall be the ratio of (x) the number of shares of Common Stock held by such Participant to (y) the total number of shares of Common Stock held by all Participants and the Founder. 
  
 (e) Each Participant shall effect its participation in the sale by promptly
delivering to the Founder for transfer to the prospective purchaser one or more certificates, properly endorsed for transfer, which represent: 
  
 (i) the type and number of shares of the Company’s common stock which such Participant elects to sell; or 
  
 (ii) that number of shares of Preferred Stock which is at such time
convertible into the number of shares of the Company’s common stock which such Participant elects to sell; provided, however, that if the prospective purchaser objects to the delivery of Preferred Stock in lieu of the Company’s common
stock, such Participant shall convert such Preferred Stock into the Company’s common stock and such common stock as provided in subparagraph 1(e)(i) above. The Company agrees to make any such conversion concurrent with the actual transfer of
such shares to the purchaser. 
  
 (f) The stock certificate or
certificates that the Participant delivers to the Founder pursuant to paragraph 1(e) shall be transferred to the prospective purchaser in consummation of the sale of the Stock pursuant to the terms and conditions specified in the Notice, and the
Founder shall concurrently therewith remit to such Participant that portion of the sale proceeds to which such Participant is entitled by reason of its participation in such sale. To the extent that any prospective purchaser or purchasers prohibits
such assignment or otherwise refuses to purchase shares or other securities from a Participant exercising its rights of co-sale hereunder, the Founder shall not sell to such prospective purchaser or purchasers any Stock unless and until,
simultaneously with such sale, the Founder shall purchase such shares or other securities from such Participant. 
  

 2 

 (g) The exercise or non-exercise of the rights of the Participants hereunder to participate in one or
more sales of Stock made by the Founder shall not adversely affect their rights to participate in subsequent sales of Stock subject to paragraph 1(a). 
  
 2. Exempt Transfers. 
  
 (a) Notwithstanding the foregoing, the co-sale rights of the Stockholders shall not apply to (i) the sale or transfer of up to an aggregate of
Twenty-Five Thousand (25,000) shares of Stock in one or more transactions by each Founder; (ii) any pledge of Stock made pursuant to a bona fide loan transaction that creates a mere security interest, (iii) any transfer to the ancestors, descendants
or spouse or to trusts for the benefit of such persons or a Founder; (iv) any transfer by Brobeck, Phleger & Harrison LLP to or between its investment funds or to attorneys of the firm; or (v) any bona fide gift; provided that (A) the
transferring Founder shall inform the Company of such pledge, transfer or gift prior to effecting it and (B) the pledgee, transferee or donee shall furnish the Company and the Stockholders with a written agreement to be bound by and to comply with
all provisions of Section 1. Such transferred Stock shall remain “Stock” hereunder, and such pledgee, transferee or donee shall be treated as a “Founder” for purposes of this Agreement. 
  
 (b) Notwithstanding the foregoing, the provisions of Section 1 shall not
apply to the sale of any Stock (i) to the public pursuant to a registration statement filed with, and declared effective by, the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”) or (ii)
to the Company, its officers or another Founder. 
  
 3.
Prohibited Transfers. 
  
 (a) In the event a Founder
should sell any Stock in contravention of the co-sale rights of the Stockholders under this Agreement (a ”Prohibited Transfer”), the Stockholders, in addition to such other remedies as may be available at law, in equity or hereunder, shall
have the put option provided below, and the Founder shall be bound by the applicable provisions of such option. 
  
 (b) In the event of a Prohibited Transfer, each Stockholder shall have the right to sell to the Founder the type and number of shares of Stock equal to
the number of shares each Stockholder would have been entitled to transfer to the purchaser had the Prohibited Transfer under Section 1(c) hereof been effected pursuant to and in compliance with the terms hereof. Such sale shall be made on the
following terms and conditions: 
  
 (i) The price per share at
which the shares are to be sold to the Founder shall be equal to the price per share paid by the purchaser to the Founder in the Prohibited Transfer. The Founder shall also reimburse each Stockholder for any and all fees and expenses, including
legal fees and expenses incurred pursuant to the exercise or the attempted exercise of the Stockholder’s rights under Section 1. 
  
 (ii) Within ninety (90) days after the later of the dates on which the Stockholder (A) received written notice of the Prohibited Transfer or (B)
otherwise became aware of the Prohibited Transfer, each Stockholder shall, if exercising the option created hereby, deliver to the Founder the certificate or certificates representing shares to be sold, with each certificate to be properly endorsed
for transfer. 
  
 (iii) The Founder shall, upon receipt of the
certificate or certificates for the shares to be sold by a Stockholder, pursuant to this subparagraph 3(b), pay the aggregate purchase price therefor and the amount of reimbursable fees and expense, as specified in subparagraph 3(b)(i), in cash or
by other means acceptable to the Stockholder. 
  

 3 

 (iv) Notwithstanding the foregoing, any attempt by a Founder to transfer Stock in violation of Section 1
hereof shall be void and the Company agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such shares without the written consent of a majority in interest of the Stockholders. 
  
 4. Legend. 
  
 (a) Each certificate representing shares of Stock now or hereafter owned by
the Founders or issued to any person in connection with a transfer pursuant to Section 2(a) hereof shall be endorsed with the following legend: 
  

			
	 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN AMENDED AND
RESTATED STOCKHOLDERS AGREEMENT BY AND BETWEEN THE STOCKHOLDER, THE CORPORATION AND CERTAIN HOLDERS OF STOCK OF THE CORPORATION AS THE SAME MAY BE AMENDED FROM TIME TO TIME. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE
SECRETARY OF THE CORPORATION.
	 	 

  
 (b) Each Founder
agrees that the Company may instruct its transfer agent to impose transfer restrictions on the shares represented by certificates bearing the legend referred to in Section 4(a) above to enforce the provisions of this Agreement and the Company agrees
to promptly do so. The legend shall be removed upon termination of this Agreement. 
  
 5. Drag-Along Right. 
  
 (a) Applicability. In the event that a majority of the Board of Directors of the Company (the “Board”) and both (i) the holders of at least a majority of the Preferred Stock then outstanding voting together as a single
class and (ii) the holders of at least a majority of the Preferred Stock and the Company’s common stock then outstanding voting together as a single class (collectively, the “Proposing Holders”) approve a Corporate Transaction (as
defined below), then the Board and the Proposing Holders shall have the right to require all other Founders and all other Stockholders (all other Founders and Stockholders are collectively referred to in this Section 5 as the “Remaining
Holders”) to vote in favor of such Corporate Transaction. If the Board and the Proposing Holders desire to approve such Corporate Transaction, each of the Remaining Holders further agrees to vote for, consent to and otherwise raise no
objections to such Corporate Transaction, and (i) if such Corporate Transaction is structured as a consolidation, merger or asset sale of the Company, or a sale of all of substantially all of the Company’s assets, the Remaining Holders shall
waive any dissenters’ rights, appraisal rights or similar rights in connection with such consolidation, merger or asset sale, or (ii) if such Corporate Transaction is structured as a sale of the capital stock of the Company, each of the
Remaining Holders shall agree to sell all shares of the Company’s capital stock held by them on the terms and conditions approved by the Proposing Holders; provided, however such terms do not provide that the Remaining Holders would
receive less than the amount that would be distributed to such Remaining Holders in the event the proceeds of such Corporate Transaction were distributed in accordance with the Company’s Amended and Restated Certificate of Incorporation then in
effect. The Remaining Holders shall take all reasonably necessary and desirable actions approved by the Board and the Proposing Holders in 
  

 4 

 connection with the consummation of such Corporate Transaction, including executing such agreements and instruments and
taking such other actions as may be necessary to (i) effectuate the allocation and distribution of the aggregate consideration received in connection with such Corporate Transaction and (ii) provide the representations, warranties, indemnities,
covenants, conditions, non-competition agreements, escrow agreements and other provisions and agreement relating to such Corporate Transaction; provided, however, that the Remaining Holders shall not be required to make any representations or
warranties in connection with such transfer other than representations and warranties as to (i) such Remaining Holder’s ownership of its capital stock to be transferred free and clear of all liens, claims and encumbrances, (ii) such
stockholder’s power and authority to effect such transfer and (iii) such matters pertaining to compliance with securities laws as the transferee may reasonably require, except that the transferee may not require that stockholder be an
accredited investor. 
  
 Notwithstanding the foregoing, no
Remaining Holder will be obligated to participate in a Corporate Transaction unless each of the following conditions are satisfied: (A) the only covenants that such Remaining Holder is required to make in connection with such Corporate Transaction
are reasonable covenants regarding confidentiality, publicity and similar matters; (B) the liability of such Remaining Holder with respect to any representation and warranty or covenant made by the Company in connection with such Corporate
Transaction is limited to a pro rata share of an escrow of the aggregate of the consideration payable to all stockholders of the Company, other than with respect to the representations and warranties made by such Remaining Holder in connection with
such Corporate Transaction with respect to such Remaining Holder’s ownership of its capital stock to be transferred free and clear of all liens, claims and encumbrances; (C) such Remaining Holder is provided an opinion of counsel to the effect
that the sale in connection with such Corporate Transaction is not in violation of the registration or qualification requirements of Canadian, United States federal or applicable United States state securities laws, or, if such Remaining Holder is
not provided with such an opinion, the Company is obligated to indemnify such Remaining Holder for any such violation; (D) such Remaining Holder is not obligated to make any out-of-pocket expenditure prior to the consummation of such Corporate
Transaction (excluding modest expenditures for postage, copies, etc.), and is not obligated to pay any expenses incurred in connection with a consummated Corporate Transaction, except indirectly to the extent such costs are incurred for the benefit
of all of the Company’s stockholders and are paid by the Company or the acquiring party (it being understood that costs incurred by or on behalf of such Remaining Holder for its sole benefit will not be considered costs incurred in connection
with a Corporate Transaction hereunder); and (E) such Remaining Holder is not required to agree to any covenant not to compete or covenant not to solicit customers, employees or suppliers of any party to the Corporate Transaction. 
  
 (b) Corporate Transaction. As used herein, a “Corporate
Transaction” means any of the following transactions: (i) a merger or consolidation in which the Company is not the surviving entity; (ii) the sale, transfer or other disposition of all or substantially all of the Corporation’s assets; or
(iii) any transaction (other than an issuance of shares by the Corporation for cash) in or by means of which one or more persons acting in concert acquire, in the aggregate, more than 50% of the outstanding shares of the stock of the Company.

  
 (c) Notice of Corporate Transaction. The Board and the
Proposing Holders shall give the Remaining Holders at least ten (10) days prior written notice of any Corporate Transaction as to which the Board and the Proposing Holders intend to exercise their rights under this Section 5. If the Board and the
Proposing Holders elect to exercise their rights under this Section 5, the Remaining Holders shall take such actions as may be reasonably required and otherwise cooperate in good faith with the Proposing Holders in connection with consummating the
Corporate Transaction. At the closing of the Corporate Transaction, the Remaining Holders shall deliver certificates for all shares of capital stock to be sold by the Remaining Holders, if any, duly endorsed for transfer, with the signature
guaranteed, to the purchaser against payment of the appropriate purchase price. 
  

 5 

 6. Miscellaneous. 
  
 6.1 Future Holders of Stock. The Company shall require any future holder (a “Future Holder”) of at least
Two Hundred Thousand (200,000) shares of Stock or an option to purchase at least Two Hundred Thousand (200,000) shares of Stock (or any combination thereof), who is not otherwise a party to this Agreement, to execute a counterpart signature page to
this Agreement such that the Future Holder shall become a party to and bound by this Agreement as if the Future Holder were a Founder, without the need of further action, signature or approval by the other parties hereto. 
  
 6.2 Governing Law. This Agreement shall be governed by and construed
under the laws of the State of California. 
  
 6.3
Amendment. Any provision may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only by the written consent of (i) as to the Company, only by the
Company, (ii) as to the Stockholders, by persons holding more than fifty percent (50%) in interest of the Common Stock held by the Stockholders and their assignees, pursuant to Section 6.4 hereof, and (iii) as to the Founders, by persons holding
more than fifty percent (50%) in interest of the Common Stock held by the Founders; provided that any amendment or waiver that by its terms expressly affects one Stockholder or Founder in a manner that is different from the other Stockholders
or Founders, as the case may be, shall require the consent of the Stockholder or Founder so affected; provided further, that any Stockholder may waive any of his rights hereunder without obtaining the consent of any other Stockholder;
provided further, Section 6.1 may be amended only by the written consent of the Company and by persons holding more than fifty percent (50%) in interest of the Common Stock held by the Stockholders and their assignees, pursuant to Section 6.4
hereof. Subject to the foregoing provisions, any amendment or waiver effected in accordance with clauses (i), (ii) and (iii) of this paragraph shall be binding upon each Stockholder, its successors and assigns, the Company and each Founder.

  
 6.4 Assignment of Rights. This Agreement and the
rights and obligations of the parties hereunder shall inure to benefit of, and be binding upon, their respective successors, assigns and legal representatives. The rights of the Stockholders hereunder are only assignable (i) by each of such
Stockholders to any other Stockholder, (ii) to an assignee or transferee who acquires all of the Common Stock then owned by a Stockholder or (iii) if a Stockholder is a partnership or limited liability company to such Stockholder’s partners or
former partners or members or former members, as applicable. 
  
 6.5 Term. This Agreement shall terminate upon the earlier of (a) the closing of the sale of the Company’s common stock in a firm commitment, underwritten public offering registered under the Securities Act of 1933, as amended
(the “Act”) other than a registration relating solely to a transaction under Rule 145 under such Act (or any successor thereto) or to an employee benefit plan of the Company, in which the public offering price (before deduction of
underwriters’ discounts and expenses) is equal to or exceeds $2.10 per share of the Company’s common stock (as adjusted for any stock dividends, combinations or splits with respect to such shares) and with gross proceeds to the Company
and/or any selling stockholders of not less than $60,000,000; and (b) the closing of the Company’s sale of all or substantially all of its assets or the acquisition of the Company by another entity by means of merger or consolidation resulting
in the exchange of the outstanding shares of the Company’s capital stock for securities or consideration issued, or caused to be issued, by the acquiring entity or its subsidiary. 
  
 6.6 Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given upon personal delivery to the party to be notified or upon deposit with a nationally recognized overnight courier service, 
  

 6 

 postage prepared and addressed to the party to be notified at the address indicated for such party on the signature page
hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties. Notwithstanding the foregoing, the telephone notice permitted by Section 1(d) shall be effective at the time it is
given. 
  
 6.7 Severability. In the event one or more of
the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement
shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
  
 6.8 Attorney Fees. In the event that any dispute among the parties to this Agreement should result in litigation, the prevailing party in such
dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
  
 6.9 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Purchasers of Series C Preferred Stock in a subsequent sale pursuant to Section 1.3 of the Purchase Agreement shall execute counterpart signature pages to this Agreement and shall become parties hereto
without the need of further action, signature or approval by the other Stockholders, under Section 6.3 of this Agreement or otherwise. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 7 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  
 COMPANY: 
  

					
	 	 	 SALMEDIX, INC.,

	 	 	 a Delaware corporation

			
	 	 	 By:
  
	 	 /s/ DAVID S. KABAKOFF

	 	 	 	 	 David S. Kabakoff

	 	 	 Its:
	 	 Chief Executive Officer

		
	 Address:
	 	 9380 Judicial Drive

	 	 	 San Diego, California 92121

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 FOUNDERS: 
  

					
	 	 	 THE DAVID S. AND SUSAN O.
 KABAKOFF FAMILY TRUST, DATED
 FEBRUARY 24, 2000

			
	 	 	 By:
  
	 	 /s/ DAVID S. KABAKOFF, TRUSTEE

	 	 	 	 	 David Kabakoff

	 	 	 Its:
	 	 Trustee

		
	 Address:
	 	 Post Office Box 9151

	 	 	 Rancho Santa Fe, CA 92067

		
	 	 	 THE DENNIS AND SANDRA CARSON
 FAMILY TRUST OF 1986, DATED
 MARCH 12, 1986

			
	 	 	 By:
  
	 	 /s/ DENNIS CARSON, TRUSTEE

	 	 	 	 	 Dennis Carson

	 	 	 Its:
	 	 Trustee

		
	 Address:
	 	  

		
	 	 	 FRANCIS A. NARDELLA

			
	 	 	 By:
  
	 	 /s/ FRANCIS A. NARDELLA

	 	 	 	 	 Francis A. Nardella

		
	 Address:
	 	 9885 North 78th Place
 Scottsdale, AZ 85258

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 LORENZO LEONI

			
	 	 	 By:
  
	 	 /s/ LORENZO LEONI

	 	 	 	 	 Lorenzo Leoni

		
	 Address:
	 	 3908 Via Tranquilo
 San Diego, CA 92122

		
	 	 	 ALAN ROSENTHAL

			
	 	 	 By:
  
	 	 /s/ ALAN ROSENTHAL

	 	 	 	 	 Alan Rosenthal

		
	 Address:
	 	 1510 Virginia Way
 La Jolla, CA 92037

		
	 	 	 BROBECK, PHLEGER & HARRISON LLP

			
	 	 	 By:
  
	 	

			
	 	 	 Its
  
	 	

		
	 Address:
	 	  

		
	 	 	 WENDY JOHNSON

			
	 	 	 By:
  
	 	 /s/ WENDY JOHNSON

	 	 	 	 	 Wendy Johnson

		
	 Address:
	 	 5350 Renaissance Ave.
 San Diego, CA 92122

		
	 	 	 ANITA BUSQUETS

			
	 	 	 By:
  
	 	 /s/ ANITA BUSQUETS

	 	 	 	 	 Anita Busquets

		
	 Address:
	 	 3366 Valemont Street
 San Diego, CA 92106

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 DENNIS CARSON

			
	 	 	 By:
	 	 /s/ DENNIS CARSON

	 	 	 	 	 Dennis Carson

		
	 Address:
	 	  

		
	 	 	 DAVID S. KABAKOFF

			
	 	 	 By:
	 	 /s/ DAVID S. KABAKOFF

	 	 	 	 	 David S. Kabakoff

		
	 Address:
	 	  

		
	 	 	 ELIZABETH CLARK MOORE

			
	 	 	 By:
	 	 /s/ ELIZABETH CLARK MOORE

	 	 	 	 	 Elizabeth Clark Moore

		
	 Address:
	 	 13639 Winstanley Way
 San Diego, CA 92130

		
	 	 	 F. ANDREW DORR

			
	 	 	 By:
	 	 /s/ F. ANDREW DORR

	 	 	 	 	 F. Andrew Dorr

		
	 Address:
	 	  

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 GARY ELLIOT

			
	 	 	 By:
	 	 /s/ GARY ELLIOT

	 	 	 	 	 Gary Elliot

		
	 Address:
	 	 11646 Compass Point Dr. N. Apt. 125
 San Diego, CA 92126

		
	 	 	 PRATIK MULTANI

			
	 	 	 By:
	 	 /s/ PRATIK MULTANI

	 	 	 	 	 Pratik Multani

		
	 Address:
	 	 10486 Harvest View Way
 San Diego, CA 92128

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 STOCKHOLDERS: 
  

					
	 	 	 INTERWEST PARTNERS VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 2710 Sand Hill Road
 Menlo Park, CA 94025

		
	 	 	 INTERWEST INVESTORS VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 2710 Sand Hill Road
 Menlo Park, CA 94025

		
	 	 	 INTERWEST INVESTORS Q VIII, L.P.

			
	 	 	 By:
	 	 InterWest Management Partners VIII, LLC

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    ARNOLD L. ORONSKY

	 	 	 	 	 Arnold L. Oronsky

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 2710 Sand Hill Road
 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 VERSANT VENTURE CAPITAL I, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260
 Menlo Park, CA 94025

		
	 	 	 VERSANT SIDE FUND I, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260
 Menlo Park, CA 94025

		
	 	 	 VERSANT AFFILIATES FUND I-A, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260
 Menlo Park, CA 94025

		
	 	 	 VERSANT AFFILIATES FUND I-B, L.P.

			
	 	 	 By:
	 	 /s/    BRIAN ATWOOD

	 	 	 	 	 Brian Atwood

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 3000 Sand Hill Road
 Building 1, Suite 260
 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

							
	 	 	 	 	 ALEXANDRIA EQUITIES, LLC,
 a Delaware limited liability company

				
	 	 	 	 	 By:
	 	 ARE-QRS CORP., a Maryland corporation

	 	 	 	 	 	 	 
				
	 	 	 By:
	 	 	 	 /s/    JOEL S. MARCUS

	 	 	 	 	 	 	 Joel S. Marcus

	 	 	 Its:
	 	 	 	 Chief Executive Officer

		
	 Address:
	 	 135 North Los Robles Avenue
 Suite
250
 Pasadena, California 91101

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 CMEA VENTURES LIFE SCIENCES 2000, L.P.

			
	 	 	 By:
	 	 /s/    M. SCHREIBSTEIN

			
	 	 	 Its:
	 	 General Partner

		
	 Address:
	 	 One Embarcadero Center, Suite 3250
 San Francisco, CA 94111
 ATTN: Meryl L. Schreibstein

		
	 	 	 CMEA VENTURES LIFE SCIENCES 2000,
 Civil Law Partnership

			
	 	 	 By:
	 	 /s/    M. SCHREIBSTEIN

			
	 	 	 Its:
	 	 General Partner

		
	 Address:
	 	 One Embarcadero Center, Suite 3250
 San Francisco, CA 94111
 ATTN: Meryl L. Schreibstein

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 DELPHI VENTURES V, L.P.

			
	 	 	 By:
	 	 Delphi Management Partners V, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    DEEPA PAKIANATHAN

	 	 	 Its:
	 	 Managing Member

		
	 Address:
	 	 3000 Sand Hill Road
 Suite 135, Building 1
 Menlo Park, CA 94025

		
	 	 	 DELPHI BIOINVESTMENTS V, L.P.

			
	 	 	 By:
	 	 Delphi Management Partners V, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    DEEPA PAKIANATHAN

	 	 	 Its:
	 	 Managing Member

		
	 Address:
	 	 3000 Sand Hill Road
 Suite 135, Building 1
 Menlo Park, CA 94025

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 ABERDARE VENTURES II, L.P.

			
	 	 	 By:
	 	 Aberdare GP II, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 Paul H. Klingenstein

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 One Embarcadero Center, Suite 4000
 San Francisco, CA 94111

		
	 	 	 ABERDARE VENTURES II (Bermuda), L.P.

			
	 	 	 By:
	 	 Aberdare GP II, L.L.C.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 Paul H. Klingenstein

	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 One Embarcadero Center, Suite 4000
 San Francisco, CA 94111

		
	 	 	 PAUL H. KLINGENSTEIN

			
	 	 	 By:
	 	 /s/    PAUL H. KLINGENSTEIN

	 	 	 	 	 An individual investor

		
	 Address:
	 	 One Embarcadero Center, Suite 4000
 San Francisco, CA 94111

		
	 	 	 JOHN H. ODDEN

			
	 	 	 By:
	 	 /s/    JOHN H. ODDEN

	 	 	 	 	 An individual investor

		
	 Address:
	 	 One Embarcadero Center, Suite 4000
 San Francisco, CA 94111

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 VENTURES WEST 7 LIMITED PARTNERSHIP

			
	 	 	 By:
	 	 Ventures West 7 Management Ltd.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 /s/    SAM [illegible]

	 	 	 Its:
	 	 Senior Vice President

			
	 	 	 By:
	 	 /s/    HOWARD RIBACK

	 	 	 	 	 Howard Riback

	 	 	 Its:
	 	 Vice President, Finance and Administration

		
	 Address:
	 	 1285 West Pender Street
 Vancouver, B. C. V6E 4B1

		
	 	 	 VENTURES WEST 7 U.S. LIMITED PARTNERSHIP

			
	 	 	 By:
	 	 Ventures West 7 Management (International) Inc.

	 	 	 Its:
	 	 Manager

			
	 	 	 By:
	 	 /s/    SAM [illegible]

	 	 	 Its:
	 	 Senior Vice President

			
	 	 	 By:
	 	 /s/    HOWARD RIBACK

	 	 	 	 	 Howard Riback

	 	 	 Its:
	 	 Vice President, Finance and Administration

		
	 Address:
	 	 1285 West Pender Street
 Vancouver, B. C. V6E 4B1

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 BIOFRONTIER GLOBAL INVESTMENT PARTNERSHIP
 a Japanese civil law partnership

			
	 	 	 By:
	 	 Biofrontier Partners Co., Ltd.

	 	 	 Its:
	 	     General Partner

			
	 	 	 By:
	 	 /s/    YOSHIHIRO OHTAKI

	 	 	 	 	 Yoshihiro Ohtaki

	 	 	 Its:
	 	     President

		
	 Address:
	 	 K.I. Kousan Tokyo Building, 3rd Floor
 2-3-14 Yaesu,
Chuo-ku
 Tokyo, Japan 104-0028

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

							
	 	 	 GENECHEM THERAPEUTICS VENTURE FUND L.P.

			
	 	 	 By:
	 	 GeneChem Therapeutics, Inc.

	 	 	 Its:
	 	 General Partner

				
	 	 	 	 	 By:
	 	 GeneChem Management, Inc.

				
	 	 	 	 	 By:
  
	 	 /s/    LOUIS LACASSE

	 	 	 	 	 	 	 Louis Lacasse

	 	 	 	 	 Its:
	 	 President

		
	 Address:
	 	 1001, de Maisonneuve O., Suite 920

	 	 	 Montreal, Quebec

	 	 	 Canada H3A 3C8

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 PROQUEST INVESTMENTS II, L.P.

			
	 	 	 By:
  
	 	 /s/    PASQUALE DEANGELIS

	 	 	 	 	 Pasquale DeAngelis

	 	 	 Its:
	 	 Chief Financial Officer

		
	 	 	 PROQUEST INVESTMENTS II ADVISORS FUND, L.P.

			
	 	 	 By:
  
	 	 /s/    PASQUALE DEANGELIS

	 	 	 	 	 Pasquale DeAngelis

	 	 	 Its:
	 	 Chief Financial Officer

		
	 	 	 QS MEDIX INC.

			
	 	 	 By:
  
	 	 /s/    CRAIGMUIR CHAMBERS

			
	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 Craigmuir Chambers

	 	 	 P.O. Box 71

	 	 	 Road Town Tortola

	 	 	 British Virgin Islands

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 H.I.G. SALMEDIX, INC.

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/    [illegible]

			
	 	 	 Its:
	 	 
		
	 Address:
	 	 H.I.G. Salmedix, Inc.

	 	 	 c/o Maples & Calder

	 	 	 P.O. Box 309, Ugland House

	 	 	 South Church Street, George Town

	 	 	 Grand Cayman, Cayman Islands

		
	 	 	 With copies to:

		
	 	 	 Aaron Davidson

	 	 	 Managing Director

	 	 	 H.I.G. Ventures

	 	 	 1001 Brickell Bay Drive

	 	 	 27th Floor

	 	 	 Miami, FL 33131

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 EASTON HUNT CAPITAL PARTNERS, L.P.

			
	 	 	 By:
	 	 EHC GP, L.P.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
	 	 EHC, Inc.

	 	 	 Its:
	 	 General Partner

			
	 	 	 By:
  
	 	 /s/ RICHARD P. SCHNEIDER

	 	 	 	 	 Richard P. Schneider

			
	 	 	 Its:
	 	 Vice President & Secretary

			
	 Address:
	 	 	 	 641 Lexington Avenue - 21st floor
 New York, NY 10022

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 HUNT VENTURES, L.P.

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/ FULTON MURRAY III

			
	 	 	 Its:
	 	 Managing Director

		
	 Address:
	 	 1445 Ross Avenue

	 	 	 Suite 1500

	 	 	 Dallas, TX 75202

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 NOVO A/S

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/ [illegible]

			
	 	 	 Its:
	 	 
			
	 Address:
	 	 	 	 NOVO A/S
 Krogshojvej 41
 DK-2880 Bagsvaerd

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 CLARIDEN BANK, as custodian for the Clariden
 Biotech Equity Fund

			
	 	 	 By:
	 	 
	 	 	 Its:
	 	 
			
	 	 	 By:
  
	 	 /s/ E. [illegible]

			
	 	 	 Its:
	 	 Executive Vice President

			
	 Address:
	 	 	 	 

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

					
	 	 	 CADUCEUS PRIVATE INVESTMENTS II, LP

			
	 	 	 By:
	 	 OrbiMed Capital II LLC

			
	 	 	 	 	 /s/ [illegible]

	 	 	 	 	 General Partner

	 	 	 	 	 OrbiMed Capital LLC

	 	 	 	 	 767 3rd Avenue, 30th Floor

	 	 	 	 	 New York, NY 10017

	 	 	 	 	 Attn: Eric Bittelman, CFO

		
	 	 	 CADUCEUS PRIVATE INVESTMENTS II (QP), LP

			
	 	 	 By:
	 	 OrbiMed Capital II LLC

			
	 	 	 	 	 /s/ [illegible]

	 	 	 	 	 General Partner

	 	 	 	 	 OrbiMed Capital LLC

	 	 	 	 	 767 3rd Avenue, 30th Floor

	 	 	 	 	 New York, NY 10017

	 	 	 	 	 Attn: Eric Bittelman, CFO

		
	 	 	 UBS JUNIPER CROSSOVER FUND, L.L.C.

			
	 	 	 By:
	 	 OrbiMed Advisors LLC

			
	 	 	 	 	 /s/ [illegible]

	 	 	 	 	 Member of UBS Juniper Crossover

	 	 	 	 	 Management, L.L.C.

	 	 	 	 	 Managing Member

		
	 Address:
	 	 PFPC Trust

	 	 	 8800 Tinicum Blvd., 3rd Floor

	 	 	 Philadelphia, PA 19153

	             Attn: Eric Kessler

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

			
	 SG COWEN SECURITIES CORPORATION

		
	 By:
  
	 	 /s/ CHARLES E. MATHER

		
	 Its:
  
	 	 Managing Director

		
	 Address:
  
	 	 1221 Ave. of Americas
 New York, NY
10020

  
 [SIGNATURE PAGE
TO AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT] 

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    SANDRA CARSON

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    SUSAN O. KABAKOFF

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    CARLA LEONI

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    CYNTHEA C. ROSENTHAL

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    MARY NARDELLA

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    RAYMOND JOHNSON

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    WILL G. LADD

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /s/    Theresa J. [Illegible]

	 (Signature of Spouse)

 CONSENT OF SPOUSE  
 (FOR SHARES OF STOCK HELD BY INDIVIDUALS) 
  
 I acknowledge that I have read the foregoing Amended and Restated Stockholders’ Agreement and that I know its contents. I am aware that by its provisions if I and/or my spouse agree to sell all or part of the
shares of the Company held of record by either or both of us, including my community interest in such shares, if any, co-sale rights (as described in the Amended and Restated Stockholders’ Agreement) must be granted to the Stockholders by the
seller. I hereby agree that those shares and my interest in them, if any, are subject to the provisions of the Amended and Restated Stockholders’ Agreement and that I will take no action at any time to hinder operation of, or violate, the
Amended and Restated Stockholders’ Agreement. 
  

	
	 /S/    [ILLEGIBLE] MULTANI

	 (Signature of Spouse)

 SCHEDULE A 
  
 Founders 
  
 The Dennis and Sandra Carson Family Trust of 1986, dated March 12, 1986 
 Fran
Nardella 
 The David S. and Susan O. Kabakoff Family Trust, dated February 24, 2000 
 Lorenzo Leoni 
 Alan Rosenthal 
 Brobeck, Phleger & Harrison LLP 
 Wendy Johnson 
 Anita Busquets 
 Dennis Carson 
 David S. Kabakoff

 Elizabeth Clark Moore 
 F. Andrew Dorr 
 Gary Elliot 
 Pratik Multani 
  
 Stockholders 
  
 InterWest Partners VII, L.P. 
 InterWest
Investors VIII, L.P. 
 InterWest Investors Q VIII, L.P. 
 Versant
Venture Capital I, L.P. 
 Versant Side Fund I, L.P. 
 Versant
Affiliates Fund I-A, L.P. 
 Versant Affiliates Fund I-B, L.P. 
 Alexandria Equities, LLC 
 CMEA Ventures Life Sciences 2000, L.P. 
 CMEA Ventures Life Sciences 2000, a Civil Law Partnership 
 Delphi Ventures V, L.P. 
 Delphi BioInvestments V, L.P. 
 ProQuest Investments II, L.P. 
 ProQuest Investments II Advisors Fund, L.P. 
 Ventures West 7 Limited
Partnership 
 Ventures West 7 U.S. Limited Partnership 
 Biofrontier Global Investment Partnership 
 GeneChem Therapeutics Venture Fund L.P. 
 Aberdare Ventures II, L.P. 
 Aberdare Ventures II (Bermuda), L.P. 
 Paul H. Klingenstein 
 John H. Odden 
 H.I.G. Salmedix, Inc. 
 Caduceus Private Investments II, LP 
 Caduceus Private Investments II (QP), LP 
 UBS Juniper Crossover Fund, LLC

 Easton Hunt Capital Partners, L.P. 
 Hunt Ventures, L.P.

 Novo A/S 
 Clariden Bank 
 QS Medix Inc. 
 SG Cowen Securities Corporation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]